Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 6, 2009, Pages 507-511

  Brar, Vikram S ^a   Sharma, Rajesh K ^a   Murthy, Ravi K ^a   Chalam, Kakarla V ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PROPIDIUM IODIDE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL COUNT; CELL DEATH; CELL VIABILITY; CHOROID; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; NONHUMAN; PIGMENT EPITHELIUM; RETINA GANGLION CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; CHOROID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HAPLORHINI; HUMANS; MICROSCOPY, FLUORESCENCE; RATS; RETINAL GANGLION CELLS; RETINAL PIGMENT EPITHELIUM; SPECIES SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77149166301     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0028     Document Type: Article

References (19)

1. Adamis, A.P., Miller, J.W., Bernal, M.-T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-450, 1994.
2. Tripathi, R.C., Li, J., Tripathi, B.J., et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 105:232-237, 1998.
3. Seddon, J., and Chen, C. The epidemiology of age related macular degeneration. In: Heier, J., ed. Controversies and Advancement in the Treatment of Retinal Disease. Philadelphia: Lippincott Williams & Wilkins; 2004; p. 17-39.
4. Hera, R., Keramidas, M., Peoc'h, M., et al. Expression of VEGF and angiopoietins in subfoveal membranes from patients with agerelated macular degeneration. Am. J. Ophthalmol. 139:589-596, 2005.
5. Green, W.R. Histopathology of age-related macular degeneration. Mol. Vision 5:27-36, 1999.
6. Medeiros, N.E., and Curcio, C.A. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 42:795-803, 2001.
7. Gibran, S.K., Sachdev, A., Stappler, T., et al. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br. J. Ophthalmol. 91(5):602604, 2007.
8. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113:363-372, 2006.
9. Spaide, R.F., Laud, K., Fine, H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina. 26:383-390, 2006. (Pubitemid 44197628)
10. Bashshur, Z.F., Haddad, Z.A., Schakal, A., et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 145:249-256, 2008.
11. Luthra, S., Narayanan, R., Marques, L.E.A., et al. Evaluation of in vitro Effects of Bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 26:512-518, 2006.
12. Spitzer, M.S., Wallenfels-Thilo, B., Sierra, A., et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br. J. Ophthalmol. 90:1316-1321, 2006.
13. Sharma, R.K., Chalam, K.V. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol. 87(6):618-622, 2009.
14. Sayanagi, K., Iktuno, Y., Soga, K., et al. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol. 87:460-463, 2009.
15. Widenfalk, J., Lipson, A., Jubran, M., et al. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience. 120:951-960, 2003.
16. Saint-Geniez, M., Maharaj, A.S.R., Walshe, T.E., et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE. 3:e3554, 2008.
17. Shahar, J., Avery, R.L., Heilweil, G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 26(3):262-269, 2006.
18. Campochiaro, P.A. Ocular or extraocular neovascularization: mirror images or vague resemblances. Invest. Ophthalmol. Vis. Sci. 47:462-474, 2006.
19. Avci, B., Avci, R., Inan, U.U., et al. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest. Ophthalmol. Vis. Sci. 50:3438-3446, 2009.